PolyPeptide Group AG

LSE:0AAJ Stock Report

Market Cap: CHF 1.3b

PolyPeptide Group Valuation

Is 0AAJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 0AAJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 0AAJ (CHF37.3) is trading above our estimate of future cash flow value (CHF13.32)

Significantly Below Future Cash Flow Value: 0AAJ is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0AAJ?

Key metric: As 0AAJ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0AAJ. This is calculated by dividing 0AAJ's market cap by their current revenue.
What is 0AAJ's PS Ratio?
PS Ratio3.5x
Sales€389.33m
Market Cap€1.37b

Price to Sales Ratio vs Peers

How does 0AAJ's PS Ratio compare to its peers?

The above table shows the PS ratio for 0AAJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
ONT Oxford Nanopore Technologies
6.2x18.16%UK£1.4b
DXRX Diaceutics
3.1x19.03%UK£121.1m
HVO hVIVO
1.1x7.19%UK£57.0m
IXI IXICO
2.6x15.14%UK£18.9m
0AAJ PolyPeptide Group
3.5x14.93%CHF 1.3b

Price-To-Sales vs Peers: 0AAJ is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (3.3x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 0AAJ's PS Ratio compare vs other companies in the European Life Sciences Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
0AAJ 3.5xIndustry Avg. 3.4xNo. of Companies6PS02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0AAJ is expensive based on its Price-To-Sales Ratio (3.5x) compared to the European Life Sciences industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is 0AAJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0AAJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.5x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: 0AAJ is expensive based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0AAJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 37.30
CHF 35.79
-4.05%
16.15%CHF 43.67CHF 25.34n/a6
May ’27CHF 38.21
CHF 36.04
-5.69%
16.16%CHF 43.99CHF 25.52n/a6
Apr ’27CHF 29.70
CHF 35.59
+19.84%
16.31%CHF 44.61CHF 25.38n/a6
Mar ’27CHF 25.70
CHF 37.07
+44.25%
10.04%CHF 43.32CHF 32.32n/a5
Feb ’27CHF 27.30
CHF 36.16
+32.47%
13.29%CHF 44.00CHF 28.68n/a6
Jan ’27CHF 25.94
CHF 34.84
+34.32%
15.03%CHF 43.97CHF 28.90n/a6
Dec ’26CHF 25.17
CHF 34.58
+37.37%
15.05%CHF 43.71CHF 28.73n/a6
Nov ’26CHF 26.06
CHF 35.32
+35.50%
14.97%CHF 43.50CHF 28.59n/a5
Oct ’26CHF 23.84
CHF 35.58
+49.25%
14.87%CHF 43.92CHF 28.86n/a5
Sep ’26CHF 27.25
CHF 34.91
+28.11%
16.24%CHF 44.06CHF 28.95n/a4
Aug ’26CHF 22.55
CHF 27.81
+23.34%
31.07%CHF 37.86CHF 18.50n/a4
Jul ’26CHF 20.40
CHF 27.81
+36.34%
31.07%CHF 37.86CHF 18.50n/a4
Jun ’26CHF 21.43
CHF 27.98
+30.62%
31.57%CHF 38.09CHF 18.62n/a4
May ’26CHF 18.80
CHF 27.98
+48.82%
31.57%CHF 38.09CHF 18.62CHF 38.214
Apr ’26CHF 16.90
CHF 29.79
+76.26%
36.38%CHF 44.54CHF 18.81CHF 29.704
Mar ’26CHF 20.65
CHF 36.07
+74.66%
20.12%CHF 45.02CHF 25.59CHF 25.704
Feb ’26CHF 25.95
CHF 36.07
+38.98%
20.12%CHF 45.02CHF 25.59CHF 27.304
Jan ’26CHF 28.40
CHF 36.17
+27.37%
17.76%CHF 44.99CHF 29.86CHF 25.943
Dec ’25CHF 29.20
CHF 36.17
+23.88%
17.76%CHF 44.99CHF 29.86CHF 25.173
Nov ’25CHF 31.65
CHF 36.17
+14.29%
17.76%CHF 44.99CHF 29.86CHF 26.063
Oct ’25CHF 30.20
CHF 26.84
-11.11%
25.17%CHF 33.63CHF 18.64CHF 23.845
Sep ’25CHF 34.10
CHF 27.78
-18.52%
22.93%CHF 34.16CHF 18.93CHF 27.256
Aug ’25CHF 29.70
CHF 25.84
-12.99%
22.31%CHF 33.51CHF 19.18CHF 22.556
Jul ’25CHF 28.85
CHF 25.84
-10.42%
22.31%CHF 33.51CHF 19.18CHF 20.406
Jun ’25CHF 32.55
CHF 24.50
-24.73%
20.89%CHF 31.04CHF 19.33CHF 21.435
May ’25CHF 30.30
CHF 21.65
-28.54%
21.21%CHF 30.15CHF 16.91CHF 18.805
CHF 35.22
Fair Value
5.9% overvalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/30 05:56
End of Day Share Price 2026/05/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PolyPeptide Group AG is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles PitmanBarclays
Estelle BétriseyBerenberg
Patrick Andrew WoodBofA Global Research